Selvester score predicts implantable cardioverter defibrillator shocks in patients with non-ischemic cardiomyopathy

被引:1
|
作者
Arisoy, Fazil [1 ]
Ozcan Celebi, Ozlem [2 ]
Erbay, Ilke [2 ]
Tufekcioglu, Omac [2 ]
Aydogdu, Sinan [2 ]
Temizhan, Ahmet [2 ]
机构
[1] Kilis State Hosp, Dept Cardiol, Kilis, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Cardiol, Ankara, Turkey
关键词
ICD; non ischemic cardiomyopathy; Selvester score; shock; SUDDEN CARDIAC DEATH; QRS SCORE; PRIMARY PREVENTION; THERAPY; MANAGEMENT; AMIODARONE;
D O I
10.1002/joa3.12571
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The implantable cardiac defibrillator is the cornerstone of prevention of sudden cardiac death in non-ischemic cardiomyopathy. The Selvester score, which is frequently investigated in ischemic cardiomyopathy, has not been investigated in the field of non-ischemic cardiomyopathy. Aim: The aim of this study was to evaluate the Selvester score for determining appropriate implantable cardiac defibrillator shocks in non-ischemic cardiomyopathy patients. Materials and methods: In all, 131 non-ischemic cardiomyopathy patients were included in the study. A simplified Selvester score was calculated from ECG data. Patients were divided into two groups according to whether they received ICD shock. Results: Of the patients, 28.2% received appropriate implantable cardiac defibrillator shock. The Selvester score was significantly higher in patients receiving appropriate shock when compared to patients with no implantable cardiac defibrillator shocks (8.8 +/- 4.6 vs 7.2 +/- 3.3, P = .040). The median QRS duration was significantly longer in patients receiving appropriate shock than in patients with no shocks (130.14 +/- 35.08 ms vs 120.12 +/- 20.57 ms, P = .045). We determined that the cutoff value for the Selvester score to predict ICD shocks was 6.5 with a sensitivity of 72.0% and a specificity of 83% (AUC = 0.717; %95 GA: 0.627-0.807, P < .001). Conclusion: Selvester score was higher in patients receiving appropriate shock than in patients who did not receive any implantable cardiac defibrillator shock. From this study, the Selvester score is associated with the risk of ventricular tachycardia/ventricular fibrillation in non-ischemic cardiomyopathy so that careful attention is necessary to manage the patients with high Selvester score.
引用
收藏
页码:1046 / 1051
页数:6
相关论文
共 50 条
  • [41] Longer and Faster Non-sustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy Patients Predicts for Implantable Cardioverter Defibrillator Shocks and Sudden Cardiac Death
    Wang, Weijia
    Lian, Zhesi
    Rowin, Ethan
    Maron, Martin
    Link, Mark
    CIRCULATION, 2015, 132
  • [42] All-cause mortality and incidence of appropriate therapy from a primary preventive implantable cardioverter defibrillator in patients with non-ischemic dilated cardiomyopathy
    Nguyen, T. M.
    Melichova, D.
    Salte, I. M.
    Gjertsen, E.
    Heggelund, G.
    Kleiven, O.
    Brunvand, H.
    Edvardsen, T.
    Haugaa, K.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [43] All-cause mortality and incidence of appropriate therapy from a primary preventive implantable cardioverter defibrillator in patients with non-ischemic dilated cardiomyopathy
    Nguyen, T. M.
    Melichova, D.
    Salte, I. M.
    Gjertsen, E.
    Heggelund, G.
    Kleiven, O.
    Brunvand, H.
    Edvardsen, T.
    Haugaa, K.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [44] Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials
    Romero, Jorge
    Chaudhary, Rahul
    Garg, Jalaj
    Lupercio, Florentino
    Shah, Neeraj
    Gupta, Rahul
    Nazir, Talha
    Bozorgnia, Babak
    Natale, Andrea
    Di Biase, Luigi
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2017, 49 (03) : 263 - 270
  • [45] CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy
    Keil, Laura
    Chevalier, Celeste
    Kirchhof, Paulus
    Blankenberg, Stefan
    Lund, Gunnar
    Muellerleile, Kai
    Magnussen, Christina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [46] Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials
    Jorge Romero
    Rahul Chaudhary
    Jalaj Garg
    Florentino Lupercio
    Neeraj Shah
    Rahul Gupta
    Talha Nazir
    Babak Bozorgnia
    Andrea Natale
    Luigi Di Biase
    Journal of Interventional Cardiac Electrophysiology, 2017, 49 : 263 - 270
  • [47] Age and effect of implantable cardioverter-defibrillator (ICD) in patients with non-ischemic systolic heart failure.
    Elming, M. B.
    Nielsen, J. C.
    Haarbo, J.
    Videbaek, L.
    Korup, E.
    Olesen, L. L.
    Steffensen, F. H.
    Bruun, N. E.
    Eiskjaer, H.
    Brandes, A.
    Svendsen, J. H.
    Hoefsten, D.
    Pehrson, S.
    Koeber, L.
    Thune, J. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 344 - 344
  • [48] Implantable cardioverter-defibrillator shocks
    Raitt, Merritt H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) : 1366 - 1368
  • [49] Clinical outcomes of implantable cardioverter defibrillators in heart failure: a comparative analysis between ischemic and non-ischemic cardiomyopathy patients
    Ferreira Neves, I. Ines
    Lopes, J.
    Portugal, G.
    Teixeira, A. R.
    Silva Cunha, P.
    Valente, B.
    Lousinha, A.
    Osorio, P.
    Santos, H.
    Monteiro, A.
    Cruz Ferreira, R.
    Martins Oliveira, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 264 - 265
  • [50] Superior quality of life in patients with non-ischemic dilated cardiomyopathy and implantable cardioverter-defibrillators: Results from the defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) study
    Passman, R
    Anderson, KP
    Subacius, H
    Schaechter, A
    Howard, A
    Calkins, H
    Kadish, A
    CIRCULATION, 2004, 110 (17) : 625 - 625